TP53 and neoplasm: In 2011, Rajeshkumar and associates reported that 25/49 pancreatic xenograft tumours with mutant p53 showed a 50% reduction in initial tumour mass when the WEE-1 inhibitor (WEE-1i) MK-1775 was added to gemcitabine treatment compared to just 7/55 treated with gemcitabine alone [95].